Skip to main content

Once-Weekly Efsitora Noninferior to Degludec for Type 2 Diabetes

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 13, 2024.

By Elana Gotkine HealthDay Reporter

FRIDAY, Sept. 13, 2024 -- Once-weekly efsitora is noninferior to once-daily degludec for reducing glycated hemoglobin levels in adults with type 2 diabetes who have not received insulin, according to a study published online Sept. 10 in the New England Journal of Medicine to coincide with the annual meeting of the European Association for the Study of Diabetes, held from from Sept. 9 to 13 in Madrid.

Carol Wysham, M.D., from the MultiCare Rockwood Center for Diabetes and Endocrinology in Spokane, Washington, and colleagues conducted a 52-week, treat-to-target trial involving adults with type 2 diabetes who had not previously received insulin. Participants were randomly assigned to receive efsitora (466 patients) or degludec (462 patients).

The researchers found that from baseline to week 52, there was a decrease in the mean glycated hemoglobin level from 8.21 to 6.97 percent with efsitora and from 8.24 to 7.05 percent with degludec (estimated treatment difference, 0.09 percentage points), with the results demonstrating noninferiority. In participants using and not using glucagon like peptide-1 receptor agonists, efsitora was noninferior to degludec with respect to change in the glycated hemoglobin level. The percentage of time that the glucose level was within target range was 64.3 and 61.2 percent with efsitora and degludec, respectively (estimated treatment difference, 3.1 percentage points). The rate of combined clinically significant or severe hypoglycemia was 0.58 and 0.45 events per participant-year of exposure with efsitora and degludec, respectively (estimated rate ratio, 1.30).

"Noninferiority to once-daily degludec with respect to the change in the glycated hemoglobin level from baseline to week 52 was shown," the authors write.

Several authors disclosed ties to the pharmaceutical industry, including Eli Lilly, which funded the study.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted September 2024

Read this next

Time-Restricted Eating Helps to Improve Diabetes Outcomes

FRIDAY, Sept. 13, 2024 -- Time-restricted eating (TRE) may improve diabetes outcomes, independent of energy intake, according to a study presented at the annual meeting of the...

Weight Reduction Varies for Patients Receiving Semaglutide, Liraglutide

FRIDAY, Sept. 13, 2024 -- For patients with obesity receiving semaglutide or liraglutide, weight reduction at one year is associated with medication active agent, dosage...

Exposure to Glucocorticoids Increases Risk for New-Onset Diabetes

WEDNESDAY, Sept. 11, 2024 -- Exposure to systemic glucocorticoids during hospitalization is associated with an increased risk for new-onset diabetes, according to a study...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.